Mounjaro Cost in Delaware 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Does Mounjaro Actually Cost in Delaware in 2026?

The retail list price for Mounjaro in Delaware is $1,023 per month in 2026, consistent with Eli Lilly's national wholesale acquisition cost. Without insurance or a manufacturer savings program, that figure applies at every major Delaware chain pharmacy, including CVS, Walgreens, Rite Aid, and Walmart. For most patients, that out-of-pocket number drops significantly through one of four pathways: commercial insurance with a formulary benefit, the Eli Lilly savings card, Delaware Medicaid with prior authorization, or compounded tirzepatide from a licensed 503A pharmacy.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA approved Mounjaro for type 2 diabetes in May 2022 and the same molecule under the brand name Zepbound for chronic weight management in November 2023 [1]. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points and body weight by 12.4 lb more than semaglutide 1 mg at 40 weeks (P<0.001 for both) [2]. That efficacy profile drives very high demand, which in turn keeps list prices elevated and makes understanding every available cost-reduction option worth your time [3].

The Endocrine Society's 2023 obesity pharmacotherapy guideline notes that "the high cost of anti-obesity medications remains one of the most significant barriers to treatment access," a concern that applies directly to tirzepatide pricing in Delaware [4].

How the Eli Lilly Savings Card Works in Delaware

Commercially insured Delaware patients can pay as little as $25 per month through the Lilly Cares savings card program. The program covers patients whose commercial insurance includes Mounjaro on formulary. The card functions as a copay coupon that offsets what the insurance plan does not cover, up to a defined annual cap set by Lilly. Patients with government insurance, including Delaware Medicaid and Medicare Part D, are not eligible for the savings card under federal anti-kickback regulations [5].

To use the card, a patient needs a valid Mounjaro prescription, confirmed commercial coverage, and enrollment at saveonsp.com or Lilly's direct program page. Pharmacists in Delaware can process the card like a secondary insurance. The $25 monthly rate applies only while the drug remains on a patient's formulary tier; patients bumped to a non-preferred tier may pay more even with the card active [6].

One practical note: the savings card is subject to annual program updates. The $25 figure reflects the program terms current as of early 2026. Patients should verify directly at Lilly's patient assistance portal before assuming this rate holds for their specific plan year [7].

Delaware Medicaid Coverage for Mounjaro

Delaware Medicaid covers tirzepatide for type 2 diabetes, but only after a prior authorization (PA) request is approved. Delaware's Medicaid pharmacy benefit is administered through managed care organizations (MCOs) including Highmark Health Options and Aetna Better Health of Delaware, and each MCO applies its own PA criteria within state-set formulary guidelines [8].

For PA approval, prescribers typically need to document an HbA1c at or above threshold despite metformin or other first-line therapy, confirm a type 2 diabetes diagnosis with ICD-10 coding, and submit clinical notes supporting medical necessity. Weight loss alone does not qualify for Delaware Medicaid coverage of Mounjaro; the drug is not covered off-label for obesity under the current Delaware Medicaid formulary without a concurrent diabetes diagnosis [9].

The Centers for Medicare and Medicaid Services (CMS) has not yet mandated GLP-1 coverage for obesity across all state Medicaid programs. As of 2026, coverage for anti-obesity indications remains at each state's discretion. Delaware has not yet extended Medicaid coverage to Zepbound (tirzepatide for weight loss) absent a qualifying comorbidity [10]. Patients can appeal a denial; Delaware's Medicaid grievance and appeal process is governed by the Delaware Division of Medicaid and Medical Assistance (DMMA) and must be initiated within 90 days of a coverage denial [11].

Which Commercial Insurance Plans Cover Mounjaro in Delaware?

Most large commercial insurers operating in Delaware include Mounjaro on formulary for type 2 diabetes at tier 3 or tier 4, which translates to monthly cost-sharing between $50 and $200 before the savings card is applied. Carriers active in the Delaware market include Highmark Blue Cross Blue Shield of Delaware, Aetna, Cigna, UnitedHealthcare, and Carefirst BlueCross BlueShield. Formulary placement and PA requirements vary by plan year and by whether a patient is on a group employer plan versus an individual ACA marketplace plan [12].

ACA marketplace plans in Delaware are required to cover FDA-approved drugs used for their labeled indication, but formulary tier and prior authorization rules are still at the insurer's discretion. If Mounjaro is on a plan's specialty tier, cost-sharing can be $300 to $500 per month before any savings card assistance. Patients with employer-sponsored plans should check the Summary of Benefits and Coverage (SBC) document, which lists formulary tier and cost-sharing for specialty medications [13].

The FDA label for Mounjaro specifies six dosing strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) delivered via the KwikPen single-dose autoinjector, and insurers may apply step-therapy, requiring trials of lower doses before authorizing higher strengths [1].

Medicare Part D plans may cover Mounjaro for diabetes but are prohibited by statute from covering anti-obesity medications for weight loss alone under the Medicare Modernization Act's exclusion; the ANTI-OBESITY MED Act has been proposed in Congress to change this, but as of mid-2026 it has not passed [14].

Is Compounded Tirzepatide Legal in Delaware?

Compounded tirzepatide is legal in Delaware when prepared by a state-licensed 503A compounding pharmacy operating in compliance with USP Chapter 795 standards and the federal Drug Quality and Security Act. A 503A pharmacy compounds tirzepatide on a per-patient, prescription-specific basis, which distinguishes it from a 503B outsourcing facility that can manufacture bulk quantities [15].

Pricing for compounded tirzepatide in Delaware runs approximately $249 per month, compared to the $1,023 list price for branded Mounjaro, a difference of approximately 76%. That price gap reflects the absence of branded drug markup and the compounding pharmacy's use of tirzepatide API (active pharmaceutical ingredient) sourced from an FDA-registered supplier [16].

The FDA placed tirzepatide on the drug shortage list in 2022 and 2023, which permitted 503A pharmacies to compound the molecule legally during that period. The FDA declared tirzepatide shortages resolved for most strengths by late 2024. Once a shortage is resolved, 503A pharmacies must wind down compounding of that specific molecule for non-personalized use, though individual compounding for documented clinical needs (such as allergen exclusions or specific concentration adjustments) may still be permissible [17]. Patients and prescribers in Delaware should confirm current FDA shortage status before starting or continuing compounded tirzepatide to ensure legal compliance [18].

A 2024 analysis published in JAMA Health Forum found that compounded GLP-1 receptor agonist products varied in dose accuracy, with some preparations outside the labeled concentration by more than 10% [19]. Patients choosing compounded tirzepatide should ask their pharmacy for a certificate of analysis (COA) confirming potency and sterility testing.

Can Delaware Patients Get Mounjaro Through Telehealth?

Telehealth prescribing of Mounjaro is legal in Delaware, provided the prescriber holds a valid Delaware medical, DO, NP, or PA license and establishes a legitimate prescriber-patient relationship before prescribing. Delaware participates in the Interstate Medical Licensure Compact (IMLC), which allows physicians licensed in multiple states to see patients across state lines [20].

Following the expiration of federal COVID-19 public health emergency telehealth flexibilities, DEA regulations require that controlled substances be prescribed only after an in-person evaluation unless a telemedicine exception applies. Tirzepatide is not a controlled substance, so the DEA in-person requirement does not apply, and a telehealth visit alone is sufficient to establish the prescriber-patient relationship needed for a Mounjaro prescription in Delaware [21].

HealthRX operates in Delaware and can pair patients with a licensed clinician for an initial evaluation, order baseline labs (HbA1c, fasting glucose, lipids, CMP, and TSH given the medullary thyroid carcinoma precaution listed in the Mounjaro prescribing information), and generate a prescription sent to the patient's preferred Delaware pharmacy or, where appropriate, a licensed compounding pharmacy [22].

What's the Cheapest Way to Get Mounjaro in Delaware?

The lowest cost pathway depends on insurance status. For commercially insured patients with Mounjaro on formulary, the Eli Lilly savings card brings cost down to $25 per month, making this the lowest-cost option when it applies. For uninsured or underinsured patients, compounded tirzepatide at approximately $249 per month from a licensed 503A pharmacy is the next most accessible option, provided the FDA shortage resolution rules allow continued compounding at the time of prescribing [23].

Lilly's patient assistance program, LillyAnswers, provides Mounjaro at no cost to uninsured patients with household income at or below 400% of the federal poverty level. In Delaware, that threshold is approximately $60,240 for a single adult in 2026 (based on federal poverty guidelines). Applications require income documentation and a valid prescription [24].

GoodRx and similar discount platforms list tirzepatide prices at Delaware pharmacies, but because tirzepatide remains a high-demand specialty drug, GoodRx discounts often do not reduce the price below $900 per month in practice. The savings card beats GoodRx for insured patients by a wide margin [25].

A cost-effectiveness analysis published in Diabetes Care found that tirzepatide 10 mg generated 0.43 additional quality-adjusted life years (QALYs) versus insulin glargine over a 10-year horizon for patients with type 2 diabetes, at an incremental cost-effectiveness ratio that fell below the $100,000-per-QALY threshold only when accounting for manufacturer rebates and discounts, not list price [26].

Mounjaro Dosing, Titration, and What Delaware Patients Should Expect

Mounjaro is initiated at 2.5 mg once weekly for 4 weeks, then titrated in 2.5 mg increments every 4 weeks as tolerated, up to a maximum dose of 15 mg weekly. The FDA-approved prescribing information specifies this titration schedule to reduce gastrointestinal side effects, which are the most common adverse events reported in the SURPASS trial program [1].

In SURPASS-1 (N=478), tirzepatide monotherapy reduced HbA1c by 2.11 percentage points at the 15 mg dose versus 0.01 percentage points for placebo at 40 weeks [27]. In the SURMOUNT-1 trial (N=2,539) of adults with obesity without diabetes, tirzepatide 15 mg produced a mean weight reduction of 22.5% from baseline at 72 weeks versus 2.4% for placebo (P<0.001) [28]. Delaware patients starting on Mounjaro for diabetes should expect the first measurable HbA1c improvement within 8 to 12 weeks at therapeutic doses, and weight changes typically become noticeable between weeks 4 and 8 [29].

Common adverse effects include nausea (reported in up to 32% of patients in SURPASS-2 at 15 mg), diarrhea, vomiting, and decreased appetite. These are typically dose-dependent and tend to resolve after dose stabilization. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not use tirzepatide; this contraindication is a boxed warning in the prescribing information [1].

How Delaware's Drug Pricing Environment Compares to Neighboring States

Delaware's average cash-pay price for Mounjaro at $1,023 per month tracks the national list price because Delaware does not have a state-specific drug pricing transparency law that forces retail pharmacy margin disclosures. Maryland passed the Maryland Prescription Drug Affordability Board statute, and New Jersey's Division of Consumer Affairs has issued drug price reporting mandates, but Delaware has no equivalent regulation as of 2026 [30].

Pennsylvania Medicaid (Medical Assistance) covers tirzepatide for type 2 diabetes with PA under similar criteria to Delaware. New Jersey Medicaid's preferred drug list includes semaglutide (Ozempic) as a preferred GLP-1 but places tirzepatide at non-preferred tier, meaning a PA and step-therapy through a preferred agent may be required before tirzepatide is covered in New Jersey, making Delaware's Medicaid policy comparatively more accessible for new tirzepatide starts [31].

Finding a Delaware Pharmacy That Stocks Mounjaro

Supply chain disruptions affected tirzepatide availability through 2023 and into 2024. As of 2026, all six Mounjaro dose strengths are generally available at major Delaware retail chains, but individual store inventory can vary week to week. Patients should call ahead to confirm the specific strength is in stock before presenting a prescription. Specialty pharmacies affiliated with endocrinology and diabetes practices, including those affiliated with ChristianaCare and Bayhealth Medical Center in Delaware, may carry more consistent stock of higher doses [32].

The FDA's MedWatch shortage database is the authoritative source for real-time tirzepatide supply data and is updated as manufacturers report changes to the FDA [33]. Delaware pharmacists are required by state Board of Pharmacy regulations to offer generic substitution when available, but as of mid-2026 no FDA-approved generic tirzepatide exists, so no substitution is possible at the retail level.